STX-478-101

BMS CA244-0001

MK-3120-002-00

DS2243-054

REGN7075

F60089IV101

IMA402-101

PANTUMOR 1479-0009

222730

ANV600-001

IMC-R117C-1004

SGNCEA5C-001

STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

STX-721-101

D6900C00001

M22TGA

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

GO43860

XL092-001

INCB 123667-101

PROACTIVE

CyPep-1

VHIO17002

A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors



<ul id="block-b900ec12-c696-4fd2-87a6-a9e347afef8d" class="wp-block-list">
<li>Code NKI: M24BBL</li>



<li>Code firma: BMS CA244-0001</li>



<li>Code clinicaltrials.gov: NCT06618287</li>
</ul>



Principal Investigator



Dr. Ruiter



Drugs



<ul class="wp-block-list">
<li>BMS-986507 (EGFRxHER3-ADC) + Osimertinib</li>



<li>BMS-986507 (EGFRxHER3-ADC) + pembrolizumab</li>
</ul>



<h2 class="wp-block-heading" id="block-c9bb39fc-6264-4a7d-a14b-2dd4aa21bac2">Summary</h2>



The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors



Read more on <a href="https://clinicaltrials.gov/study/NCT06618287">clinicaltrials.gov</a>.



<h2 class="wp-block-heading">Additional comments</h2>



Open